Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GART | P22102 | 13/20 | 0.62 |
| ▸ | FOLR1 | P15328 | 11/20 | 0.56 |
| ▸ | SLC46A1 | Q96NT5 | 8/20 | 0.56 |
| ▸ | SLC19A1 | P41440 | 5/20 | 0.56 |
| ▸ | FOLR2 | P14207 | 4/20 | 0.56 |
| ▸ | ATIC | P31939 | 5/20 | 0.55 |
| ▸ | SHMT1 | P34896 | 3/20 | 0.52 |
| ▸ | SHMT2 | P34897 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1065440 | 1.00 | GART (0.62) | GARTFOLR1SLC46A1SLC19A1FOLR2 | |
| SCHEMBL6829597 | 1.00 | GART (0.62) | GARTFOLR1SLC46A1SLC19A1FOLR2 | |
| SCHEMBL20659947 | 1.00 | GART (0.62) | GARTFOLR1SLC46A1SLC19A1FOLR2 | |
| SCHEMBL27529613 | 1.00 | GART (0.62) | GARTFOLR1SLC46A1SLC19A1FOLR2 | |
| SCHEMBL7745908 | 0.88 | GART (0.75) | GARTFOLR1SLC46A1SLC19A1FOLR2 | |
| Lometrexol SCHEMBL18530 | 0.85 | GART (0.78) | GARTFOLR1SLC46A1SLC19A1FOLR2 | |
| Lometrexol SCHEMBL21248426 | 0.85 | GART (0.77) | GARTFOLR1SLC46A1SLC19A1FOLR2 | |
| SCHEMBL9380609 | 0.82 | DHFR (0.59) | GARTFOLR1SLC46A1SLC19A1FOLR2 | |
| SCHEMBL9383067 | 0.82 | DHFR (0.59) | GARTFOLR1SLC46A1SLC19A1FOLR2 | |
| SCHEMBL9381796 | 0.82 | DHFR (0.59) | GARTFOLR1SLC46A1SLC19A1FOLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020103212-A1 | Pharmaceutical compositions containing anti-fas antibody | SANKYO COMPANY, LIMITED (JP) | 2002-08-01 | — | — | US | claimed |
| US-7981421-B2 | Combinations of antibodies selective for DR5 and other therapeutic agents | THE UAB RESEARCH FOUNDATION (US) | 2011-07-19 | — | — | US | disclosed |
| US-20110002887-A1 | COMBINATIONS OF ANTIBODIES SELECTIVE FOR DR5 AND OTHER THERAPEUTIC AGENTS | THE UAB RESEARCH FOUNDATION (US) | 2011-01-06 | — | — | US | disclosed |
| US-7704502-B2 | Combinations of antibodies selective for DR5 and other therapeutic agents | THE UAB RESEARCH FOUNDATION (US) | 2010-04-27 | — | — | US | disclosed |
| US-20090022707-A1 | Combinations of Antibodies Selective for a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor and Other Therapeutic Agents | THE UAB RESEARCH FOUNDATION (US) | 2009-01-22 | — | — | US | disclosed |
| US-7279160-B2 | Combinations of DR5 antibodies and other therapeutic agents | THE UAB RESEARCH FOUNDATION (US) | 2007-10-09 | — | — | US | disclosed |
| US-6746673-B2 | FOR PROPHYLAXIS AND/OR TREATMENT OF AN AUTOIMMUNE DISEASE OR RHEUMATOID ARTHRITIS | SANKYO COMPANY, LIMITED (JP) | 2004-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103212-A1 | Pharmaceutical compositions containing anti-fas antibody | DHFR, FOLR1, FOLR2 | GART 243/4885FOLR1 2/4885SLC46A1 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.